An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study

CONCLUSION: For individuals with crFMF, COD compared to CFF policy can achieve similar efficacy and safety, with a lower accumulated canakinumab dose, rendering it less immunosuppressive and less expensive.PMID:38569431 | DOI:10.1016/j.intimp.2024.111967

Source: International Immunopharmacology - April 3, 2024 Category: Allergy & Immunology Authors: Katy Shehadeh Yoel Levinsky Shelly Kagan Tarek Zuabi Rotem Tal Neta Hana Aviran Yonatan Butbul Aviel Irit Tirosh Shiri Spielman Adi Miller-Barmak Rotem Semo Oz Liora Harel Gabriel Chodick Gil Amarilyo Source Type: research